VanEck Biotech ETF (NASDAQ:BBH) Short Interest Down 33.8% in August

Posted by Brian Himes on Sep 19th, 2026

VanEck Biotech ETF (NASDAQ:BBH – Get Free Report) was the target of a large decrease in short interest in August. As of August 31st, there was short interest totaling 21,252 shares, a decrease of 33.8% from the August 15th total of 32,083 shares. Approximately 1.0% of the company’s shares are short sold. Based on an average trading volume of 10,054 shares, the short-interest ratio is presently 2.1 days.

VanEck Biotech ETF Stock Down 1.1%

NASDAQ:BBH opened at $234.14 on Friday. The company has a 50-day moving average of $222.48 and a 200 day moving average of $201.22. VanEck Biotech ETF has a 1-year low of $160.91 and a 1-year high of $244.35.

Insider Transactions at VanEck Biotech ETF

In related news, major shareholder Sardar Biglari sold 6,533 shares of the stock in a transaction that occurred on Wednesday, July 15th. The stock was sold at an average price of $16.71, for a total value of $109,166.43. Following the transaction, the insider owned 3,552,710 shares of the company’s stock, valued at $59,365,784.10. This represents a 0.18% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Insiders sold a total of 10,493 shares of company stock valued at $175,335 over the last quarter.

Hedge Funds Weigh In On VanEck Biotech ETF

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. LGL Partners LLC bought a new position in shares of VanEck Biotech ETF during the 2nd quarter worth approximately $2,298,000. First PREMIER Bank acquired a new stake in VanEck Biotech ETF during the 2nd quarter worth about $91,000. Proficio Capital Partners LLC acquired a new stake in shares of VanEck Biotech ETF during the second quarter worth about $5,183,000. Nwam LLC purchased a new stake in shares of VanEck Biotech ETF in the 2nd quarter valued at $18,614,000. Finally, JNBA Financial Advisors purchased a new stake in VanEck Biotech ETF in the second quarter valued at $122,000. Hedge funds and other institutional investors own 32.05% of the company’s stock.

About VanEck Biotech ETF

(Get Free Report)

The BIOTECH HOLDING COMPANY DEPOSITARY RECEIPTS or HOLDRS TRUST was formed under the depositary trust agreement, among The Bank of New York, as trustee, Merrill Lynch, Pierce, Fenner & Smith Incorporated, other depositors and the owners of the Biotech HOLDRS. The trust currently holds shares of common stock or American depositary shares issued by a group of companies that were, at the time of the initial offering, generally considered to be involved in various segments of thebiotechnology industry.